Management of Frontal Cortical Signs

Initial Diagnostic Approach

MRI head without IV contrast is the preferred initial imaging modality to characterize frontal cortical abnormalities, as it provides superior resolution for detecting cortical malformations, white matter changes, and subtle structural lesions, according to the American College of Radiology 1, 2, 3.
CT head without IV contrast serves as an acceptable alternative when MRI is contraindicated or unavailable, though it has lower sensitivity for cortical pathology, as stated by the Journal of the American College of Radiology 4.
Imaging should specifically evaluate for focal cortical dysplasia (FCD) with blurring of grey-white matter junction, cortical thickening, and transmantle sign, as well as polymicrogyria showing abnormally small gyri with stippled grey-white matter boundary, particularly in frontoparietal regions, according to Nature Reviews Neurology 1, 2, 3, 5.

Refer to epilepsy surgery center if seizures are present and medically refractory, as surgical resection of FCD type II or other focal malformations can be curative, as recommended by the American Academy of Neurology 3, 5.
Initiate antiepileptic therapy targeting the specific seizure type, recognizing that frontal lobe epilepsy from MCD often requires polytherapy, according to Translational Neurodegeneration 6.
Genetic testing should be pursued for polymicrogyria, lissencephaly spectrum disorders, and other MCDs to identify specific mutations (PRRT2, tubulin genes, LIS1, DCX) that inform prognosis and family counseling, as suggested by Nature Reviews Neurology 1, 2, 3.

Patients with subtle baseline frontal lobe impairment are at higher risk for complications, and baseline neurological examination documenting frontal signs should be performed before immunotherapy to stratify risk, although the specific guideline society is not mentioned 6.
Distinguishing frontal lobe epilepsy from movement disorders requires careful consideration of clinical presentation, including stereotypic movements, sleep occurrence, and normal interictal EEG, as discussed in Translational Neurodegeneration 6.
Kinesigenic trigger with preserved consciousness during attacks favors paroxysmal dyskinesia over epilepsy, and trial of carbamazepine or oxcarbazepine can be both diagnostic and therapeutic for paroxysmal kinesigenic dyskinesia, according to Translational Neurodegeneration 6.

Serial neuroimaging at 3-6 month intervals for progressive conditions to assess disease trajectory, as recommended by the Journal of Internal Medicine 8.
Regular neurological examination to detect early deterioration requiring intervention adjustment, although the specific guideline society is not mentioned 9.
Genetic counseling for hereditary MCDs and neurodegenerative conditions once molecular diagnosis established, as suggested by Nature Reviews Neurology 1, 2.